Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Pfizer Has Voluntarily Withdrawn All Lots of its Sickle Cell Disease Treatment OXBRYTA® from Worldwide Markets

September 26, 2024 0

Pfizer OXBRYTA® Worldwide Withdrawal Pfizer (PFE) announced today that it is voluntarily withdrawing all lots of …

The FDA Approved IntraBio Product AQNEURSA As the only treatment for Niemann-Pick Disease Type C

September 26, 2024 0

IntraBio Inc in the NEWS IntraBio Inc. announced that the FDA has approved AQNEURSA (levacetylleucine) for …

UCB And Biogen Announced Positive Topline Results Phase 3 Study of Dapirolizumab Pegol for Systemic Lupus Erythematosus

September 24, 2024 0

UCB and Biogen Positive Results UCB (Euronext Brussels: UCB) and Biogen Inc. (BIIB) announced positive . . . This …

Sanofi Product Sarclisa Approved in the US as the First anti-CD38 Therapy

September 23, 2024 0

Sanofi Approval The United States FDA approved Sanofi (SNY) product Sarclisa (isatuximab) in combination with bortezomib, …

Aligos Therapeutics Announces Positive Topline Results from Phase 2A Herald Study of ALG-055009 for the Treatment of MASH

September 20, 2024 0

Aligos Therapeutics in the NEWS Yesterday, Sept. 19, 2024, Aligos Therapeutics (ALGS) - a small clinical-stage …

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024 0

AstaZeneca Fasenra Approval AstraZeneca (AZN) product Fasenra (bevacizumab) has been approved in the US for the treatment …

The U.S. FDA Approves Novartis’ Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024 0

Novartis FDA Approval Yesterday, September 17, 2024, Novartis (NVS) announced that the United States FDA has …

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024 0

AstraZeneca Imfinzi + Imjudo Updated results from the HIMALAYA Phase III trial have demonstrated that AstraZeneca …

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024 0

Halozyme Therapeutics in the NEWS Halozyme Therapeutics, Inc. (HALO) announced that Roche received U.S. Food and …

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024 0

Johnson & Johnson FDA Approval Yesterday, September 11, 2024, Johnson & Johnson (JNJ) announced that the …

Travere Therapeutics Announces Full FDA Approval of FILSPARI®

September 11, 2024 0

Travere Therapeutics Approval Travere Therapeutics, Inc., (TVTX) announced that the U.S. FDA has granted full approval to …

Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

September 10, 2024 0

Gilead Sciences and Genesis Therapeutics Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the …

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome

September 5, 2024 0

Regenxbio Positive Results Regenxbio (RGNX) announced positive results from the Phase I/II/III CAMPSIITE® trial of RGX-121 …

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet the Growing Demand

September 4, 2024 0

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 On August 28, …

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

August 29, 2024 0

Merck Updates Merck (MRK) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, stating that …

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

August 27, 2024 0

Vertex Announces CASGEVY™ Reimbursement Agreement with NHS England Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with …

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

August 21, 2024 0

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ (GILD) …

Gilead Sciences Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

August 15, 2024 0

Gilead Sciences Approval Gilead Sciences (GILD) today announced that the U.S. FDA has granted accelerated approval …

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients with Prurigo Nodularis

August 13, 2024 0

Galderma: FDA Approval for Nemluvio® Today, August 13, 2024, Galderma (GALD.SW) announced that the U.S. FDA …

Cytokinetics Reports Management Update and Q2 2024 Financial Results

August 12, 2024 0

Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing muscle …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Pfizer Has Voluntarily Withdrawn All Lots of its Sickle Cell Disease Treatment OXBRYTA® from Worldwide Markets

The FDA Approved IntraBio Product AQNEURSA As the only treatment for Niemann-Pick Disease Type C

UCB And Biogen Announced Positive Topline Results Phase 3 Study of Dapirolizumab Pegol for Systemic Lupus Erythematosus

Sanofi Product Sarclisa Approved in the US as the First anti-CD38 Therapy

Aligos Therapeutics Announces Positive Topline Results from Phase 2A Herald Study of ALG-055009 for the Treatment of MASH

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

The U.S. FDA Approves Novartis’ Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

Travere Therapeutics Announces Full FDA Approval of FILSPARI®

Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet the Growing Demand

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Gilead Sciences Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients with Prurigo Nodularis

Cytokinetics Reports Management Update and Q2 2024 Financial Results